Tenaya Therapeutics Inc. (TNYA)
0.50
-0.02 (-3.85%)
At close: Apr 04, 2025, 3:48 PM
-3.85% (1D)
| Bid | 0.5 |
| Market Cap | 81.31M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.31 |
| PE Ratio (ttm) | -0.38 |
| Forward PE | -0.85 |
| Analyst | Buy |
| Ask | 0.5 |
| Volume | 1,997,269 |
| Avg. Volume (20D) | 3,370,077 |
| Open | 0.51 |
| Previous Close | 0.52 |
| Day's Range | 0.48 - 0.52 |
| 52-Week Range | 0.39 - 4.96 |
| Beta | 2.99 |
About TNYA
Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through cellular regeneration, gene therapy, and precision medicine platforms. The company is developing TN-201, an adeno-associated virus (AAV)-based gene therapy to address genetic hypertrophic cardiomyopathy (gHCM) caused by haploinsufficient myosin binding protein C3 (MYBPC3) gene mut...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 97
Stock Exchange NASDAQ
Ticker Symbol TNYA
Analyst Forecast
According to 5 analyst ratings, the average rating for TNYA stock is "Buy." The 12-month stock price forecast is $5.5, which is an increase of 999.78% from the latest price.
Stock Forecasts1 month ago
-53.53%
Tenaya Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
1 month ago
-6.25%
Tenaya Therapeutics shares are trading lower after the company announced its intention for a common stock offering of series A & B warrants.
